Sawyer & Company Inc Has $2.03 Million Position in Cencora, Inc. (NYSE:COR)

Sawyer & Company Inc decreased its holdings in shares of Cencora, Inc. (NYSE:COR) by 25.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,039 shares of the company’s stock after selling 3,076 shares during the quarter. Sawyer & Company Inc’s holdings in Cencora were worth $2,031,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Redhawk Wealth Advisors Inc. boosted its holdings in shares of Cencora by 8.1% during the 4th quarter. Redhawk Wealth Advisors Inc. now owns 11,292 shares of the company’s stock worth $2,537,000 after buying an additional 848 shares during the period. Thurston Springer Miller Herd & Titak Inc. lifted its position in Cencora by 71.1% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock worth $1,583,000 after acquiring an additional 2,928 shares during the last quarter. Park Avenue Securities LLC boosted its holdings in shares of Cencora by 37.0% during the fourth quarter. Park Avenue Securities LLC now owns 11,690 shares of the company’s stock worth $2,627,000 after acquiring an additional 3,156 shares during the period. Kathmere Capital Management LLC grew its position in shares of Cencora by 14.6% in the fourth quarter. Kathmere Capital Management LLC now owns 2,091 shares of the company’s stock valued at $470,000 after purchasing an additional 266 shares during the last quarter. Finally, Board of the Pension Protection Fund bought a new position in shares of Cencora during the fourth quarter worth approximately $989,000. 97.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on COR. Mizuho assumed coverage on Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective on the stock. Bank of America restated a “neutral” rating and issued a $245.00 price target (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Evercore ISI lifted their price objective on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Robert W. Baird increased their target price on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Finally, Leerink Partners dropped their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $275.60.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 94,696 shares of company stock valued at $22,862,734. Corporate insiders own 15.80% of the company’s stock.

Cencora Stock Performance

Shares of NYSE:COR opened at $237.74 on Thursday. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $253.27. The stock has a market capitalization of $45.95 billion, a price-to-earnings ratio of 31.66, a price-to-earnings-growth ratio of 1.54 and a beta of 0.49. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The company’s 50 day simple moving average is $237.79 and its 200 day simple moving average is $233.67.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a $0.55 dividend. This is a positive change from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.93%. Cencora’s dividend payout ratio (DPR) is presently 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.